Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

PURPOSE: It has been postulated that castration-resistant prostate cancer (CRPC) commonly remains hormone dependent. Abiraterone acetate is a potent, selective, and orally available inhibitor of CYP17, the key enzyme in androgen and estrogen biosynthesis. PATIENTS AND METHODS: This was a phase I/II...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Attard, Gerhardt, Reid, Alison H.M., A’Hern, Roger, Parker, Christopher, Oommen, Nikhil Babu, Folkerd, Elizabeth, Messiou, Christina, Molife, L. Rhoda, Maier, Gal, Thompson, Emilda, Olmos, David, Sinha, Rajesh, Lee, Gloria, Dowsett, Mitch, Kaye, Stan B., Dearnaley, David, Kheoh, Thian, Molina, Arturo, de Bono, Johann S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3535569/
https://ncbi.nlm.nih.gov/pubmed/19470933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.20.0642
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia